Yahoo · Mar 6, 2026
Liberate Bio gains licences for myeloid-specific CAR design patents
The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.
NASDAQ · CARM
Carisma Therapeutics, Inc.
Healthcare · Biotechnology
$0.00
Down-$0.00 (-12.00%)
Updated Aug 15, 2026, 4:33 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.04M
- P/E ratio
- -0.04
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.56
- Volume
- 2.26K
- Avg. volume
- 1.18M
Price performance
CARM price history
1M range · 19 trading sessions · Daily adjusted prices
CARM closed at $0.00 after 19 trading sessions, down 57.69% for the selected period.
- Last close
- $0.00
- Period change
- -57.69%
- Period low
- $0.00
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.0022 | $0.0022 | $0.0022 | $0.0022 | 2.26K |
| Aug 13, 2026 | $0.0023 | $0.0023 | $0.0022 | $0.0022 | 111.68K |
| Aug 11, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 577 |
| Aug 10, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 2.33K |
| Aug 7, 2026 | $0.0022 | $0.0025 | $0.0022 | $0.0025 | 48.65K |
| Aug 6, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 160 |
| Aug 5, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 4.5K |
| Aug 4, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 1.19K |
| Aug 3, 2026 | $0.0025 | $0.0025 | $0.0025 | $0.0025 | 2.76K |
| Jul 30, 2026 | $0.0025 | $0.004 | $0.0025 | $0.0025 | 7.48K |
| Jul 29, 2026 | $0.0022 | $0.0022 | $0.0022 | $0.0022 | 1.85K |
| Jul 28, 2026 | $0.0045 | $0.0045 | $0.0045 | $0.0045 | 810 |
| Jul 27, 2026 | $0.0045 | $0.0045 | $0.0045 | $0.0045 | 18.81K |
| Jul 24, 2026 | $0.0051 | $0.0051 | $0.0045 | $0.0045 | 3.18K |
| Jul 23, 2026 | $0.0051 | $0.0051 | $0.0051 | $0.0051 | 11.49K |
| Jul 22, 2026 | $0.0042 | $0.0051 | $0.0042 | $0.0045 | 35.87K |
| Jul 21, 2026 | $0.0051 | $0.0051 | $0.0042 | $0.0042 | 11.68K |
| Jul 20, 2026 | $0.0042 | $0.0042 | $0.0042 | $0.0042 | 10.89K |
| Jul 17, 2026 | $0.0052 | $0.0052 | $0.0052 | $0.0052 | 22.19K |
Latest CARM news
The latest Smart Investors Daily articles mentioning CARM.
Stock researchCompany · Overview
CARM research
Overview
Company profile and research snapshot.
Company profile
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 8, 2025 | D. Boral Capital | Buy | — |
| Apr 1, 2025 | D. Boral Capital | Buy | — |
| Jan 17, 2025 | D. Boral Capital | Buy | — |
| Jan 13, 2025 | D. Boral Capital | Buy | — |
| Dec 16, 2024 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Mar 5, 2026
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
CAMBRIDGE, Mass., March 05, 2026--Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key patents covering chimeric antigen receptor (CAR) designs optimized for myeloid cells, including monocytes and macrophages.
prnewswire.com · Dec 5, 2025
Carisma Announces Delisting from Nasdaq and SEC Deregistration
PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC ("Nasdaq") and the deregistration of its common stock in order to suspend and ultimately terminate the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). As previously reported, as a result of the Company's previously disclosed noncompliance with the bid price, market value of listed securities, and market value of publicly held shares requirements set forth in Nasdaq Listing Rules 5450(a)(1), 5450(b)(2)(C), and 5450(b)(2)(A), respectively, the Company received a delist determination letter from Nasdaq on October 9, 2025 (the "Determination Letter") and the Company's common stock was suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
